Pricing Log in Create free account

Mesoblast Limited (MESO) vs Zymeworks Inc. (ZYME)

Mesoblast Limited and Zymeworks Inc. are both Biotechnology companies. Mesoblast Limited and Zymeworks Inc. are of similar size ($1.8B and $1.8B). Mesoblast Limited grew revenue faster over the last twelve months: −26.5% against −69.8%. Zymeworks Inc. has the higher net margin (−404.0% vs −1,091.7%) and the higher return on invested capital (0.00% vs 0.00%). Across the 17 metrics below, Zymeworks Inc. leads on 9 and Mesoblast Limited on 8.

Valuation

Metric MESO ZYME Biotechnology median
P/E n/m n/m 8.50
P/S 137.69 49.29 9.71
P/B 1.80 22.77 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 137.28 42.01 9.21
Earnings yield (8.43%) (8.06%) (33.15%)
Free cash flow yield (8.17%) (6.63%) (25.50%)

Profitability

Metric MESO ZYME Biotechnology median
Gross margin (269.72%) (246.66%) 65.16%
Operating margin (826.28%) (418.99%) 0.00%
Net margin (1,091.71%) (404.00%) 0.00%
Free cash flow margin 0.00% (324.68%) 0.00%
Return on equity 0.00% (72.31%) (56.36%)
Return on assets 0.00% (37.25%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric MESO ZYME Biotechnology median
Revenue growth (TTM) (26.54%) (69.78%) 6.02%
EPS growth (last fiscal year) 48.24% 33.33% 30.26%
Revenue growth, 5-year CAGR 74.39% 22.16% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric MESO ZYME Biotechnology median
Debt to equity 0.22 0.00 0.00
Current ratio 1.58 6.32 4.72
Net debt to EBITDA (0.67) 2.81 0.96

Dividend

Metric MESO ZYME Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric MESO ZYME Biotechnology median
Market cap 1.81b 1.84b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack